pharmaphorum2d
BioAge's $100m IPO, and other biotech financings
Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...
Seeking Alpha16d
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
A Quick Take On BioAge Labs, Inc. BioAge Labs, Inc. (BIOA) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a clinical ...
Benzinga.com18d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...
pharmaphorum3d
Respiratory biotech Upstream joins Nasdaq IPO surge
queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara ...
FierceBiotech18d
UPDATE: BioAge files for IPO, plans pair of midstage obesity trials
"BioAge's IPO could serve as a bellwether for the sector, potentially catalyzing further investment and innovation," Kazi Helal, Ph.D., senior biotech analyst at PitchBook, told Fierce Biotech in ...
Reuters18d
Eli Lilly partner BioAge files for US IPO
The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. The company lost $26.6 million in the first half of ...
AOL18d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 ...